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ABSTRACT 51 
Objective 52 
Siblings of patients with Crohn’s disease (CD) have elevated risk of developing CD and display aspects of 53 
disease phenotype, including faecal dysbiosis. Whether the mucosal microbiota is disrupted in these at-risk 54 
individuals is unknown. Objective: To determine the existence of mucosal dysbiosis in siblings of CD 55 
patients using 454 pyrosequencing and to comprehensively characterise, and determine the influence of 56 
genotypic and phenotypic factors, on that dysbiosis. 57 
Design 58 
Rectal biopsy DNA was extracted from 21 patients with quiescent CD, 17 of their healthy siblings and 19 59 
unrelated healthy controls. Mucosal microbiota was analysed by 16S rRNA gene pyrosequencing and were 60 
classified into core and rare species. Genotypic risk was determined using Illumina Immuno BeadChip, 61 
faecal calprotectin by ELISA and blood T-cell phenotype by flow cytometry. 62 
Results 63 
Core microbiota of both CD patients and healthy siblings were significantly less diverse than controls. 64 
Metacommunity profiling (Bray-Curtis (SBC) index) showed the sibling core microbial composition to be 65 
more similar to CD (SBC=0.70) than to HC, whereas the sibling rare microbiota was more similar to HC 66 
(SBC=0.42). Faecalibacterium prausnitzii contributed most to core metacommunity dissimilarity both 67 
between siblings and controls, and between patients and controls. Phenotype/genotype markers of CD-risk 68 
significantly influenced microbiota variation between and within groups, of which genotype had the largest 69 
effect. 70 
Conclusion 71 
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Individuals with elevated CD-risk display mucosal dysbiosis characterised by reduced diversity of core 72 
microbiota and lower abundance of F. prausnitzii. This dysbiosis in healthy people at-risk of CD implicates 73 
microbiological processes in CD pathogenesis.  74 
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SUMMARY BOX 75 
What is already known about this subject:  76 
• Patients with CD have mucosal dysbiosis, including reduced abundance of Faecalibacterium 77 
prausnitzii 78 
• Low mucosal Faecalibacterium prausnitzii predicts relapse after surgery in CD patients 79 
• Healthy siblings of CD patients have increased risk of developing CD and have altered abundance of 80 
key species in the gut lumen 81 
What are the new findings:  82 
• There is a distinct dysbiosis in the mucosal microbiota of healthy siblings of CD patients  83 
• The sibling dysbiosis comprises a fundamental distortion of microbial community composition, 84 
most notably reduced diversity of core microbiota and low abundance of mucosal Faecalibacterium 85 
prausnitzii 86 
• Mucosal microbiota disruption is not merely a consequence of the inflammation in CD but is 87 
present at healthy individuals at risk of CD 88 
 89 
How might it impact on clinical practice in the foreseeable future?  90 
• Identification of this at risk dysbiosis signals pathways in CD pathogenesis and raises the possibility 91 
of CD risk identification and CD risk intervention  92 
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INTRODUCTION 93 
Disruption of gut microbiota (dysbiosis) is an established feature of inflammatory bowel disease (IBD). The 94 
dysbiosis in Crohn’s disease (CD) has been well described and includes reduced microbial diversity, reduced 95 
abundance of Firmicutes particularly Faecalibacterium prausnitzii, reduced abundance of Bifidobacteria, 96 
increased γ-proteobacteria and disturbances in Bacteroides populations.[1] The involvement of several CD 97 
susceptibility genes in the recognition and handling of bacteria (e.g., NOD2, ATG16L1, IRGM) reinforces the 98 
position of the gut microbiota at the centre of IBD pathogenesis.  [2, 3, 4] 99 
Whether the CD dysbiosis is involved with pathogenesis is uncertain. The dependence on the presence of 100 
gut microbiota for the development of inflammation in animal models[5] as well as CD patients,[6] and the 101 
association between reduced mucosal F. prausnitzii and post-operative relapse[7] implies a pathogenic 102 
role. Conversely, the lack of therapeutic benefit of manipulating the microbiota,[8,9] suggests that 103 
dysbiosis in CD may not drive inflammation, but rather is consequent to established disease, reflecting for 104 
example, the differential survival of various species in an inflamed environment. Moreover, attempts to 105 
identify aspects of the CD dysbiosis that were present at disease initiation, which therefore potentially have 106 
a role in pathogenesis may be obfuscated by both the mature disease phenotype of the patients studied 107 
and the effect of the medical, surgical and patient-initiated attempts to treat and control symptoms.  108 
Siblings of CD patients have a relative risk (RR) of developing CD of up to 35 times that of the general 109 
population.[10] This risk is partly genetic, but is also driven by non-genetic factors many of which they 110 
share with their CD-affected sibling.[10,11] Several of these non-genetic risk factors, such as mode of 111 
delivery, breast feeding, maternal inoculum, home environment and weaning diet,[12] potentially impact 112 
gut microbial acquisition and development. It follows that any aspect of the CD dysbiosis which is also 113 
present in a healthy sibling cannot be disrupted as a consequence of disease, and rather may be implicated 114 
in processes driving CD pathogenesis.[12] 115 
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Attempts have been made to determine whether aspects of the CD phenotype are present in patients’ 116 
unaffected relatives. These have assessed dysbiosis[13] and other features of the CD phenotype such as 117 
raised faecal calprotectin (FC), increased intestinal permeability (IP) and the presence of anti-microbial 118 
antibodies.[12]  Using PCR probes selected to detect  dominant species that comprise the dysbiosis in CD, 119 
we have previously indicated that a faecal dysbiosis exists in healthy siblings of CD patients characterised by 120 
reduced faecal Firmicutes including F. prausnitzii.[14] Moreover, we previously demonstrated in siblings 121 
that a combination of luminal dysbiosis, raised FC, reduced abundance of circulating naïve T-cells, 122 
disturbances in their expression of gut-homing β7 integrin and at-risk genotype could be combined to 123 
create a multidimensional risk phenotype, which significantly distinguished healthy siblings of CD patients 124 
from healthy, unrelated controls.[14] 125 
It has been speculated that mucosal microbiota are of greater significance in CD pathogenesis than luminal 126 
microbiota given their closer spatial relationship to the gut immune system. Yet, studies comparing 127 
mucosal microbiota in CD patients, their families and healthy controls are rare due to the invasiveness of 128 
procedures required to obtain mucosal samples from otherwise healthy individuals. However, the potential 129 
rewards of obtaining such samples have been amplified by recent advances in the analysis of large, diverse 130 
and complex microbial communities. Pyrosequencing technology and meta-community profiling enables 131 
sampling depth permitting detection not only of dominant microbial community members but also low-132 
abundance (rare) taxa.[15, 16] The capacity to characterise core and rare microbial communities separately 133 
may reveal microbial features associated with disease not otherwise readily apparent. Furthermore, 16S 134 
rRNA gene pyrosequencing and other next-generation technologies have demonstrated that microbial 135 
diversity can be orders of magnitude higher than previously appreciated.[16] Measuring diversity may be 136 
significant as healthy gut microbiota high diversity compared with microbial populations in other human 137 
body habitats.[18] Moreover, gut microbial diversity is consistently described as reduced both in CD,1 and 138 
other human diseases including obesity,[18, 19] colorectal cancer,[20] eczema,[21] and in addition has 139 
been linked with smoking.[22] 140 
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Therefore, we sought to use 454 pyrosequencing and metacommunity analysis to comprehensively 141 
characterise the structure and composition of the mucosal microbial community in an at-risk group of CD 142 
siblings compared with CD patients and healthy controls.  143 
MATERIALS AND METHODS 144 
Patients with inactive CD (Crohn’s Disease Activity Index (CDAI) <150 and C-reactive protein (CRP) ≤5mg/L, 145 
and their healthy siblings (both 16-35 years) were recruited from clinics at Barts Health NHS Trust and 146 
University College Hospitals NHS Foundation Trust (London, UK). Patients required a confirmed diagnosis of 147 
CD for >3months. All healthy siblings who volunteered and did not meet exclusion criteria (detailed in 148 
supplementary Table S1) were included, to limit bias in the selection of siblings with specific characteristics. 149 
Healthy controls were recruited by email sent to staff and students at King’s College London (London, UK), 150 
during the same period. Participants were informed that involvement in the study did not constitute 151 
screening for disease and that detection of clinical disease in any sibling or control would lead to exclusion 152 
from the study.  153 
Only participants consenting to rectoscopy and providing analysable biopsies were included. All participants 154 
provided written, informed consent. Ethical approval was provided by Bromley Local Research Ethics 155 
Committee (reference 07/H0805/46). 156 
At screening, demographics, medical and drug exposure history, physical examination, CRP, inclusion and 157 
exclusion criteria were assessed. Instructions regarding avoidance of prebiotics/probiotics for 4 weeks (to 158 
prevent impact on microbiota), non-steroidal anti-inflammatory drugs for 1 week and alcohol for 24h 159 
before the study (to prevent impact on IP) were provided. Blood samples were taken for routine 160 
haematology/biochemistry, T-cell analysis and genotyping. Participants completed a 5h urine collection for 161 
measurement of IP and underwent flexible rectoscopy without bowel cleansing. Biopsies from non-162 
inflamed rectum were snap frozen, and stored at -80⁰C before processing for histological and 163 
microbiological analyses. Stool was obtained and stored at -20⁰C before processing for FC quantification. 164 
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Faecal calprotectin 165 
FC extraction and ELISA analysis (Calpro AS, Lysaker, Norway) were carried out according to manufacturer’s 166 
instructions using duplicate appropriately diluted samples. FC concentration (µg/g) was determined relative 167 
to standard curves. 168 
Peripheral blood T-cell flow cytometry 169 
Whole blood, collected in lithium-heparin Vacutainer tubes (BD Bioscience), was stored at room 170 
temperature for ≤4 h before labelling with fluorescently conjugated monoclonal antibodies to detect CD3 T-171 
cells, naïve (CD45RA+) and memory (CD45RA−) subsets of CD4 and CD8 T-cells. Integrin α4β7 expression was 172 
assessed by labelling with anti-β7 (see supplementary methods for antibodies used). Data were acquired 173 
using a LSRII 4-colour flow cytometer (BD Bioscience) and collected using fluorescence-activated cell sorting 174 
Diva software V.4.1.2 (BD Bioscience) using Flow-Count fluorospheres (Beckman Coulter) for absolute 175 
quantitation. Colour compensation was performed offline using Winlist V.6.0 (Verity Software House). 176 
Genotyping 177 
Human DNA was extracted from whole blood using the phenol chloroform-isoamyl alcohol method. 178 
Genotyping was performed using the Illumina Infinium Immunochip.[2, 23] To increase detection of NOD2 179 
mutations and capture the enhanced risk of NOD2 compound heterozygosity, three NOD2 mutations 180 
(rs2066845/G908R, rs2066844/R702W and rs5743293/3020insC) were individually assessed. Cumulative 181 
genotype relative risk (GRR) for each participant was therefore calculated across 72 CD-risk loci. A 182 
population distribution model of CD-risk was generated using the REGENT R program[24] and previously 183 
published odds ratios.[2] Participants were categorised into reduced, average, elevated or high genotype 184 
risk with reference to this model.[25] 185 
Intestinal permeability 186 
IP was measured using lactulose-rhamnose tests as previously described.[14] 187 
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Gut mucosal microbiota 188 
Biopsy DNA extraction was carried out using a phenol/chloroform based method, as described 189 
previously.[26] A detailed extraction protocol is provided in the supplementary methods. DNA extracts 190 
were quantified using the Picodrop Microlitre Spectrophotometer (GRI, Braintree, UK). Negative controls 191 
(sterile water), were included in the DNA extraction and PCR amplification steps.  192 
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed as described previously using 193 
Gray28F 5'-TTTGATCNTGGCTCAG-3' and Gray519r 5'-GTNTTACNGCGGCKGCTG-3'.[27] Detailed protocols 194 
for 16S rRNA gene sequencing and sequence data processing are provided in the supplementary methods.  195 
To assign bacterial identities to 16S rRNA gene sequences, sequence data were de-noised, assembled into 196 
OTU clusters at 97% identity, and queried using a distributed .NEt algorithm that utilises Blastn+ 197 
(KrakenBLAST, www.krakenblast.com) against a database of high quality 16S rRNA gene bacterial 198 
sequences. Using a .NET and C# analysis pipeline the resulting BLASTn+ outputs were compiled, data 199 
reduction analysis performed, and sequence identity classification carried out, as described previously.[28] 200 
Statistical analyses 201 
Bacterial species within each metacommunity were partitioned into common and rare groups using a 202 
modification of a previously described method.[15]  Three complementary measurements of diversity were 203 
used to compare microbial diversity between samples, as previously described: species richness (S*, the 204 
total number of species), Shannon-Wiener (H’, a metric accounting for both number and relative 205 
abundance of species), and Simpson’s (1-D, a measure of the probability that two species randomly 206 
selected from a sample will differ).[15, 26] To avoid potential bias due to varying sequences per sample, all 207 
measures were calculated using randomised re-sampling to a uniform number of sequence reads per 208 
sample.[26] Mean diversity measures were calculated from the re-sampling of the reads from each 209 
specimen to the lowest number of sequence reads among all specimens for 1000 iterations. Diversity 210 
analysis was performed in R.[29] Two sample t-tests, regression analysis, coefficients of determination (r2), 211 
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residuals and significance (P) were calculated using Minitab software (version 16, Minitab, University Park, 212 
PA, USA). Canonical correspondence analysis (CCA), analysis of similarity (ANOSIM), similarity of 213 
percentages (SIMPER) analysis were performed using the PAST (Palaeontological Statistics, version 3.01) 214 
program available from the University of Oslo website link (http://folk.uio.no/ohammer/ past) run by 215 
Øyvind Hammer. The Bray-Curtis quantitative index of similarity was used as the underpinning community 216 
similarity measure for CCA, ANOSIM, and SIMPER tests.   217 
RESULTS 218 
Demographic and disease characteristics of the 21 patients with quiescent CD, 17 of their healthy siblings, 219 
and 19 unrelated healthy controls that were included are summarised in Table 1. At the time of the study 220 
only one patient was cohabiting with one of the included siblings. GRR, FC, faecal Firmicute abundance and 221 
circulating T-cell characteristics were all significantly different in both CD patients and healthy siblings 222 
compared with healthy controls as previously published,[14] and as summarised in Table 1.  223 
  224 
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Table 1 Summary of demographic variables in patients, siblings and controls as well as clinical 225 
characteristics in patients. The features of the at-risk phenotype that have previously been delineated in 226 
this cohort are also displayed. 227 
  
Patients 
(n=21) 
Siblings 
(n=17) 
Controls 
(n=19) P-value 
Mean age years, (SD) 27.7 (6.6) 25.5 (4.5) 27.7 (5.8) 0.783* 
Males, n (%)  13 (62) 11 (65) 9 (47) 0.515† 
Body Mass Index, kg/m2 (SD) 24.5 (5.0) 24.5 (3.6) 23.9 (3.4) 0.870* 
Ethnicity n (%) 
White British 17 (81) 15 (88) 17 (90) 
0.469† 
Asian/Asian 
British 
3 (14) 1 (6) 0 (0) 
Black British or 
mixed 
black/white 
1 (5) 1 (6) 2 (11) 
Smoking n (%) 
Never 14 (67) 10 (59) 12 (63) 
0.830† Current 4 (19) 5 (29) 3 (16) 
Previous  3 (14) 2 (12) 4 (21) 
Age at diagnosis, 
n (%) 
Below 16 years 7 (33)  
16-40 years 14 (67)  
Disease location, 
n (%) 
Ileal 7 (33)  
Colonic 5 (24)  
Ileocolonic 9 (43)  
Concomitant upper GI disease, n (%) 1 (5)  
Disease 
behaviour, n (%) 
Non-stricturing, 
non-penetrating 
11 (52)  
Stricturing 5 (24)  
Penetrating 5 (24)  
Perianal disease, n (%) 4 (19)  
Current 5-ASA n (%) 11 (52)  
Current immuno- 
suppressant,  
n (%) 
Azathioprine 
Mercaptopurine 
Methotrexate 
7 (33) 
2 (10) 
1 (5) 
 
Ileocaecal resection / right 
hemicolectomy, n (%) 
9 (43)  
Isolated small bowel resection, n (%) 1 (5)  
Genotype 
relative risk,ǁ n 
(%) 
High 3 (14) 1 (6) 0 (0) 
0.175† Elevated 2 (10) 3 (18) 0 (0) 
Average 10 (48) 8 (47) 8 (42) 
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Reduced 6 (29) 5 (29) 11 (58) 
Fecal calprotectin, m/g (IQR) 
281 
(144-855) 
30 
(13-83) 
13 
(7-33) 
<0.001‡ 
Faecal F. prausnitzii, % (IQR) 0.1 (0.0-2.9) 3.7 (0.4-7.1) 5.2 (2.3-7.2) 0.001‡ 
T-cells with memory phenotype, % 
(IQR) 
73 (63-82) 74 (67-83) 65 (54-70) 0.011‡ 
Naïve CD4+ T-cells, cells/ ml (IQR) 
194,132 
(71,053-
341,156) 
198,220 
(128,550-
296,351) 
380,256 
(279,118-
564,861) 
<0.001‡ 
Naïve CD4+ T-cells expressing β7 
integrin, % (IQR) 
76 (63-85) 74 (61-83) 52 (32-71) 0.003‡ 
Intestinal permeability: urinary 
lactulose-rhamnose ratio, (IQR)§ 
0.061 
(0.033-
0.111) 
0.034 
(0.024-
0.056) 
0.038 
(0.025-
0.050) 
0.081‡ 
* One-way ANOVA   228 
† Chi-squared test   229 
‡ Kruskall-Wallis test 230 
§ Data from 20 patients, 17 siblings and 16 controls contributed to the intestinal permeability analysis 231 
ǁ Cumulative genotype relative risk (GRR) for each participant was calculated across 72 CD-risk loci (detected using the Illumina 232 
Infinium Immunochip). Participants were categorised into reduced, average, elevated or high genotype risk with reference to a 233 
population distribution model of CD-risk, previously described.[14] 234 
  235 
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A total of 180,696 bacterial sequence reads (mean  per sample 3235 ± SD 205), identifying 160 genera and 236 
351 distinct operational taxonomic units (OTUs) classified to species level (Table S2), were generated from 237 
all samples combined. The numbers of bacterial sequence reads per sample were similar among the three 238 
cohorts (mean ± SD): CD, 3296 ± 258 (n =21); siblings, 3190 ± 423 (n =17); and healthy, 3210 ± 393 (n =19). 239 
Species abundance was directly correlated with distribution 240 
We have previously established that the categorisation of human microbiota into core and rare species 241 
revealed important aspects of metacommunity species-abundance distributions that would be neglected 242 
without such a distinction.[15] A coherent metacommunity could be expected to exhibit a direct 243 
relationship between prevalence and abundance of individual species within the constituent communities. 244 
Consistent with this prediction, the abundance of species in each study group significantly correlated with 245 
the number of individual sample communities those species occupied (CD (R2 =0.62, F1,227 =366.9, P < 246 
0.0001); siblings (R2 =0.71, F1,259 =590.1, P < 0.0001); and healthy controls (R2 =0.68, F1, 258 =552.6, P < 247 
0.0001)), (Fig. 1).  248 
In CD patients a lower proportion of the mucosal microbiota were core species 249 
Individual species in each cohort metacommunity were then classified as core or rare based on their falling 250 
within or outside the upper quartile of subject occupancy, respectively (Fig. 1). Of the 229 species that 251 
comprised the CD metacommunity, only 7 were core and 222 were rare species. The healthy siblings 252 
metacommunity (261 species) comprised 18 core and 243 rare species, and the healthy controls 253 
metacommunity (260 species) comprised 25 and 235 species, respectively. In addition, the core species 254 
within each cohort metacommunity accounted for 44.7% ± 4.8% (CD), 67.6%,± 5.5% (healthy siblings) and 255 
67.4% ± 4.6 (healthy controls) of the mean (± SD) relative abundance. The mean relative abundances in the 256 
CD core microbiota were significantly lower than the healthy siblings and healthy controls (P < 0.0001 in 257 
both cases), but were not different between the siblings and healthy controls (P =0.907). 258 
Microbial diversity was lower in both siblings and patients compared with controls 259 
16 
 
 
The mean microbial diversity of subject communities for each cohort was compared using three indices of 260 
diversity (Fig. 2). Diversity was compared between the three cohorts for the whole microbiota, as well as 261 
core and rare species groups (Fig. 2). These analyses revealed the siblings’ whole and core microbiota to be 262 
significantly more diverse than the CD cohort, but the sibling core microbiota was significantly less diverse 263 
than the healthy core microbiota. No significant difference in diversity was observed between the whole 264 
microbiota between the siblings and healthy cohorts, emphasising the advantage of analysing core and rare 265 
populations separately. In addition, the CD rare microbiota was significantly less diverse than the other two 266 
rare species cohorts, which in turn were not significantly different from each other. All of these 267 
observations were underpinned by all three measures of diversity in each instance (Fig. 2). 268 
Interestingly, within the CD population, diversity of the whole microbiota was lower in the nine patients 269 
with an ileocaecal resection / right hemicolectomy compared with the 11 patients without these operations 270 
(as shown by Richness P<0.0001; Shannon-Wiener P=0.046; but not Simpson’s P=0.768). This was largely 271 
driven by lower diversity of rare taxa (as shown by Richness P<0.0001; Shannon-Wiener P=0.019; but not 272 
Simpson’s P=0.159) rather than core taxa (Richness P=0.523; Simpson’s P=0.612; Shannon-Wiener 273 
P=0.824). 274 
Significant divergence in whole and core microbial composition between CD patients and healthy 275 
controls, but not between CD patients and healthy siblings 276 
The distribution of the microbiota within the three cohorts was determined by direct ordination using Bray-277 
Curtis similarity measures. Using Analysis of Similarities (ANOSIM) tests, the CD and healthy whole and core 278 
microbiota were significantly divergent from each other. However, the whole and core microbiota of 279 
siblings were not significantly divergent from either that of the CD or healthy controls (Fig. 3). In all 280 
instances rare microbiota were significantly divergent between cohorts, including between siblings and 281 
healthy controls.  282 
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Lower Faecalibacterium prausnitzii made the greatest contribution to the dissimilarity in microbiota 283 
between both healthy siblings and healthy controls and between CD and healthy controls 284 
Given the involvement of core species in differences of relative abundance, diversity and microbiota 285 
composition, the contribution of individual taxa to the dissimilarity between core microbiota was assessed 286 
by Similarities of Percentages (SIMPER) analyses (Table 2). Both F. prausnitzii and Escherichia fergusonii 287 
contributed the most to the dissimilarity between all cohorts.  As a proportion of core species F. prausnitzii 288 
had a higher relative abundance in the healthy controls (30.9%) than both the CD (22.4%) and siblings 289 
(24.2%). Conversely, E. fergusonii was more abundant in the CD cohort (21.4%) than in siblings (9.7%) and 290 
healthy controls (4.1%). 291 
  292 
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Table 2 Similarity of Percentages (SIMPER) analysis of microbial community dissimilarity (Bray-Curtis) 293 
between core species groups for (A) CD and siblings, (B) healthy and siblings, and (C) CD and healthy 294 
cohorts. Given is mean % abundance of sequences for core species only across the samples each was 295 
observed to occupy and the average dissimilarity between samples (overall mean (A) =73.4% and (B) 296 
=55.0%, (C) =73.0%). Percentage contribution is the mean contribution divided by mean dissimilarity across 297 
samples.  The list of species is not exhaustive so cumulative % value does not sum to 100%. Species level 298 
identities of detected taxa are reported here. However, given the length of the ribosomal sequences 299 
analysed, these identities should be considered putative. 300 
A Crohn's Siblings   
Name mean abundance mean abundance % Contribution Cumulative % 
Faecalibacterium prausnitzii 22.4 24.2 20.7 20.7 
Escherichia fergusonii 21.4 9.7 15.9 36.6 
Shigella flexneri 13.6 7.2 10.7 47.3 
Ruminococcus gnavus 13.1 5.2 8.9 56.2 
Bacteroides vulgatus 13.2 7.6 7.8 64.0 
Eubacterium rectale 9.8 6.4 6.6 70.6 
Oscillospira guilliermondii 0 8.0 5.9 76.5 
Escherichia coli 6.5 0 4.5 81.0 
Sutterella wadsworthensis 0 6.0 4.5 85.5 
Bacteroides dorei 0 5.7 4.2 89.6 
Roseburia faecis 0 4.0 2.9 92.6      
B Healthy Siblings   
Name mean abundance mean abundance % Contribution Cumulative % 
Faecalibacterium prausnitzii 30.9 24.2 18.9 18.9 
Escherichia fergusonii 4.1 9.7 10.6 29.5 
Sutterella wadsworthensis 8.7 6.0 9.4 38.9 
Shigella flexneri 3.6 7.2 8.4 47.3 
Bacteroides vulgatus 8.0 7.6 8.4 55.7 
Eubacterium rectale 9.9 6.4 7.0 62.8 
Oscillospira guilliermondii 8.5 8.0 7.0 69.8 
Bacteroides dorei 0 5.7 5.4 75.2 
Ruminococcus gnavus 4.1 5.2 4.1 79.3 
Bacteroides uniformis 2.9 2.0 3.1 82.4 
Roseburia faecis 2.4 4.0 3.0 85.4 
Coprococcus eutactus 2.3 0 2.2 87.7 
Shigella dysenteriae 2.1 0 2.1 89.8 
Blautia producta 2.0 1.8 1.8 91.6      
C Crohn's Healthy   
Name mean abundance mean abundance % Contribution Cumulative % 
Faecalibacterium prausnitzii 22.4 30.9 22.4 22.4 
Escherichia fergusonii 21.4 4.1 14.4 36.7 
Shigella flexneri 13.6 3.6 9.3 46.0 
Ruminococcus gnavus 13.1 4.1 8.6 54.6 
Bacteroides vulgatus 13.2 8.0 8.0 62.7 
Eubacterium rectale 9.8 9.9 7.4 70.1 
Sutterella wadsworthensis 0 8.7 6.4 76.5 
Oscillospira guilliermondii 0 8.5 6.2 82.8 
Escherichia coli 6.5 0 4.4 87.2 
Bacteroides uniformis 0 2.9 2.1 89.3 
Roseburia faecis 0 2.4 1.8 91.1 
  301 
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Genotype and phenotypic features associated with CD and CD-risk significantly explained microbiota 302 
variation 303 
Canonical correspondence analysis (CCA) was used to relate the variability in the distribution of microbiota 304 
between cohorts to clinical and demographic variables (Table 3 and Fig. 4). Variables that significantly 305 
explained variation in mucosal microbiota were determined with forward selection (999 Monte Carlo 306 
permutations; P < 0.05) and used in CCA. Based on the direct ordination approach, the microbiota between 307 
cohorts was significantly influenced by factors listed in Table 3. The same analytical approach was used to 308 
assess the extent to which variance in the microbiota distribution within cohorts could be accounted for by 309 
variation in measures of clinical and demographic factors, (Table 3).  GRR was the most significant factor in 310 
explaining variance between the three cohorts, but also within each cohort. FC was also significant in 311 
explaining variance between cohorts, particularly in the core microbiota. However, in the within-group 312 
analyses FC was significant in explaining microbial variance in patients and siblings but not in controls. 313 
Blood T-cell factors explained a higher proportion of variance in siblings and controls than in patients. 314 
Conversely, age significantly associated with variance in controls but not in patients or siblings. 315 
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Table 3 Canonical correspondence analyses for determination of percent variation in the whole, core, and rare microbiota between and within the three 316 
subject cohorts by clinical variables significant at the P < 0.05 level. * Ileal/Colonic involvement in CD patients used as a factor for the corresponding siblings. n/a 317 
denotes not applicable for between cohort or within healthy cohort analyses.  318 
  Between Cohorts Within Crohn's Within Siblings Within Healthy 
Variable Whole Core Rare Whole Core Rare Whole Core Rare Whole Core Rare 
Age - - - - - - - - - 5.37 6.08 5.08 
Blood concentration of naïve CD4+ T-cells (cells /ml) - 2.8 - 4.15 3.69 4.54 7.34 8.84 8.30 - - - 
Calprotectin 1.7 3.4 2.7 4.68 5.36 4.63 4.85 5.70 7.10 - - - 
Gender 1.8 - 2.4 5.03 - 6.20 6.04 9.12 7.03 6.31 4.57 7.19 
Genotype relative risk (GRR) 5.1 4.3 4.7 8.56 6.75 9.11 6.53 12.54 5.64 5.57 6.26 5.34 
Ileal/Colonic involvement* n/a n/a n/a 5.50 - 5.87 4.94 6.40 5.81 n/a n/a n/a 
Proportion of blood T-cells with memory phenotype (%) 2.0 - 2.4 - - - 8.71 5.77 9.24 5.19 - 6.87 
Proportion of CD4+ naïve T-cells expressing β7 integrin (%) - 3.6 - 4.85 5.84 5.19 5.30 - 7.81 5.60 10.08 4.15 
Undetermined 89.4 85.9 87.8 67.2 78.4 64.5 56.3 51.6 49.1 72.0 73.0 71.4 
* Ileal/Colonic involvement in Crohn’s patients used as a factor for the corresponding Sibling subjects. n/a denotes not appl icable for between cohort or within 319 
Healthy cohort analyses.    320 
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DISCUSSION 321 
This is the first study to detail the mucosal microbiota of clinically and genetically well-characterised 322 
healthy siblings of CD patients, and to compare them with both their CD-affected siblings and healthy 323 
controls. Moreover, this study is unique in uncovering interactions of mucosal microbiota with genotype 324 
and features of the CD-risk phenotype. This manuscript is a significant advance on the preliminary account 325 
of the multidimensional risk phenotype previously described, which centred on qPCR sampling of faecal 326 
microbiota.[14] The current study not only focuses on the mucosal microbiota but also employs next-327 
generation sequencing and advanced statistical analysis to reveal the complexity of the metacommunities 328 
in healthy siblings of CD patients. The core mucosal microbiota in siblings was characterised by lower 329 
diversity compared with controls, and lower abundance of F. prausnitzii made the greatest contribution to 330 
the dissimilarity between these two groups. Genetic CD-risk explained the highest proportion of microbial 331 
variance both between all three groups, and within the patient and sibling groups. These findings are 332 
unlikely to be confounded by cohabitation as only one patient cohabited with one sibling. 333 
Although related healthy individuals are known to harbour similar gut microbiota,[19] the similarity in the 334 
microbiota between CD patients and their healthy siblings is of considerable pathogenic relevance. Previous 335 
studies have shown that when one sibling has CD, familial microbial similarity is disrupted, even in disease-336 
discordant monozygotic twins.[30] Thus, microbial features which are similar between affected and 337 
unaffected siblings, but which are not present in low CD-risk healthy individuals, may be part of the CD-risk 338 
phenotype and therefore pertinent to CD pathogenesis. In order to discern these features associated with 339 
familial risk, comparison with healthy, unrelated individuals is essential. 340 
The validity of the data presented is supported by the correlation between species-abundance and 341 
distribution, which is consonant with a coherent metacommunity structure and is similar to distributions 342 
described in other ecological communities.[15] This feature of community structure facilitated delineation 343 
of core species which are abundant and persistent, and allowed resolution of features of the mucosal 344 
microbiota without obfuscation from rare microbiota which may be highly variable, transient and scarce. A 345 
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significantly higher proportion of the microbiota in CD patients belonged to the rare group compared with 346 
healthy siblings and healthy controls. As described below this is at least in part attributable to loss of 347 
principal members of the core group, most notably Firmicutes. 348 
Reduced microbial diversity is an almost universally reported feature of mucosal CD dysbiosis.[1] The 349 
current study reveals that core microbiota diversity is also lost in siblings of CD patients, indicating that this 350 
may be a fundamental step in CD pathogenesis. Reduced diversity may be an indicator of the health of 351 
human microbial communities, as it is reduced in a variety of disorders.[18-21] Lower diversity may be 352 
associated with incomplete occupation of ecological niches resulting in reduced resistance to pathogen 353 
colonisation; additionally a more restricted gut metagenome contains a lower array of genes which may 354 
result in the loss of key functions. 355 
Lower diversity indicates altered mucosal microbial composition, and microbial composition in CD patients 356 
and healthy controls were significantly distinct from one another. In contrast, the composition of the whole 357 
and core microbiota in healthy siblings was not significantly different from either CD patients or healthy 358 
controls, indicating that from a microbial metacommunity perspective, siblings lie somewhere between 359 
patients and controls. The greater variability in the composition of the microbiota in at-risk siblings 360 
(illustrated by larger 95% concentration ellipse in Figure 3 (panel B)) probably reflects the range of CD-risk 361 
contained within this group, with siblings with higher CD-risk lying closer to or within the CD region. In 362 
addition, diversity was lower in core and rare microbiota in patients with ileocaecal resection/ right 363 
hemicolectomy, potentially explained by differences in disease phenotype, or the absence of the ileocaecal 364 
valve that would otherwise constitute a barrier between small and large intestinal microbiota. 365 
Consonant with previous work highlighting the importance of F. prausnitzii in CD dysbiosis,[7, 12, 14] F. 366 
prausnitzii made the greatest contribution to the dissimilarity between CD patients and healthy control 367 
microbiota. The prominence of F. prausnitzii has biological significance as it is the only microbial factor 368 
shown to be predictive of the natural history of CD,[7] and response to treatment.[31] Strikingly, F. 369 
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prausnitzii was also the biggest contributor to the dissimilarity of the core mucosal microbiota between 370 
healthy siblings and healthy controls, establishing that mucosal F. prausnitzii not only correlates to the 371 
natural history of CD, but is also a key feature of the at-risk phenotype. Taken together these findings 372 
strongly support the hypothesis that depletion of F. prausnitzii is part of CD pathogenesis rather than 373 
consequent to established CD. Several mechanisms exist whereby F. prausnitzii and other Firmicutes may 374 
contribute to gut health, including the production of short-chain fatty acids (SCFAs),[32, 33] SCFA-375 
independent, NFκB-mediated effects,[7] and via production of longer-chain fatty acids such as conjugated 376 
linoleic acid.[34] 377 
The pathogenic role of reduced F. prausnitzii in CD has been questioned by a study describing increased 378 
mucosal F. prausnitzii in newly-diagnosed pediatric IBD.[35] However, whether increased abundance of F. 379 
prausnitzii is a distinctive feature of pediatric-onset IBD, with low F. prausnitzii being associated with later-380 
onset CD, or whether the abundance of F. prausnitzii may bloom in childhood and then critically decline in 381 
those at risk of CD, may only be determined by longitudinal studies. 382 
Other species contributing to the dissimilarity in the core mucosal microbiota between CD patients and 383 
healthy controls were congruent with species previously identified as characterising the CD dysbiosis, 384 
including a greater abundance of most Proteobacteria such as E. fergusonii and Escherichia coli. Similar 385 
species contributed to the dissimilarity between siblings and controls. However, the presence of E. coli was 386 
specific to CD mucosa, and therefore may be a feature of established CD rather than pathogenic. Features 387 
of the inflamed gut such as increased activity of nitric oxide synthases[36], or reduction in faecal butyrate 388 
producers which will result in a rise in pH, potentially favour the survival of organisms that are inhibited at 389 
acidic pH such as E. coli.[37] 390 
GRR was the factor associated most strongly with the variation in the microbiota in both the between-391 
group analysis, and analysis within each of the three groups. Although the proportion of variation in 392 
mucosal microbiota explained by GRR was small, it is nevertheless significant. The combination of loci used 393 
24 
 
 
to estimate GRR in the current study does not include more recently detected risk loci and can be expected 394 
to account for a limited proportion of the genetic risk.[38] Therefore, these data will tend to underestimate 395 
the effect of genotype. Furthermore, since other factors known to affect gut microbiota such as diet were 396 
not controlled, this signal of the interaction between genotype and the mucosal microbiota is striking. 397 
The direction of the vector in figure 3 illustrates that FC contributed to the axis separating patients from the 398 
other two groups in the whole, core and rare microbiota, implying that microbial composition in CD is 399 
partly associated with the degree of inflammation. This would support the hypothesis that CD-specific 400 
elements of the dysbiosis may be consequent to intestinal inflammation, through mechanisms such as the 401 
enhanced survival of E. coli in an inflamed environment as proposed above. 402 
When each group was considered separately, the effect of each factor in different groups could be 403 
compared. Several factors were significant in all groups (GRR, gender, proportion of CD4+ naïve T-cells 404 
expressing β7 integrin). Other factors were significant in patients and siblings but not controls: FC and 405 
blood naïve CD4+ T-cell concentration were significant only in patients and siblings, whereas age was 406 
significant only in controls. Disease phenotype was significant in explaining microbial variation within the 407 
CD group as would be predicted from previous studies.[30] However; we have also demonstrated that for 408 
healthy siblings, disease site in their affected relative was significantly associated with the variation in their 409 
own microbiota. This would suggest that specific risk phenotypes are associated with different disease 410 
phenotypes. 411 
Overall these factors accounted for a higher proportion of the variance in the microbial composition in 412 
siblings, compared with controls or patients, indicating that this multidimensional risk phenotype is specific, 413 
and that in low CD-risk individuals the microbial composition is associated with other factors, such as age. 414 
Furthermore, it would appear that in CD the influence of factors associated with the original risk phenotype 415 
is obfuscated by established CD and its surgical and medical management.  416 
CONCLUSION 417 
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Healthy siblings of CD patients, who themselves have elevated risk of CD, have a dysbiosis of the core 418 
mucosal microbiota characterised by reduced diversity and loss of Firmicutes, notably F. prausnitzii. 419 
Genotype determines a proportion of the at-risk mucosal microbial phenotype. Notwithstanding the 420 
limited extent to which known loci account the observed CD-risk,[39] it is also clear that the sibling risk 421 
goes beyond genotype and that non-genetic factors within families contribute to the development of an at-422 
risk microbiota. How and why patients and their siblings acquire the microbiota that marks out this risk is 423 
not known. However, knowledge of the at-risk microbial phenotype illuminates possible pathways in CD 424 
pathogenesis and raises the prospect of intervention to impact human health and influence disease risk.   425 
26 
 
 
Acknowledgements 426 
We gratefully acknowledge and thank the charity Core who funded a research fellowship for CRH which 427 
made this study possible.  428 
CvdG and LC were supported by the UK Natural Environment Research Council (grant NE/H019456/1) 429 
  430 
27 
 
 
FIGURE LEGENDS 431 
Fig. 1. The distribution and abundance of bacterial species within microbiota samples within the (a) CD, (b) 432 
siblings, and (c) healthy control cohort metacommunities. Given is the number of mucosal samples for 433 
which each bacterial taxon was observed to occupy, plotted against the mean abundance across all samples 434 
((a) n =21, r2 =0.62, F1, 227 =366.9, P < 0.0001; (b) n =17, r2 =0.71, F1, 259 =590.1, P < 0.0001; and (c) n 435 
=19, r2 =0.68, F1, 258 =552.6, P < 0.0001).  Core species were defined as those that fell within the upper 436 
quartile (dashed lines), and rare species defined as those that did not. 437 
 438 
Fig. 2. Diversity of whole, core and rare microbiota within the CD (black columns), siblings (grey), and 439 
healthy (white) control cohorts. Given are three indices of diversity; Species richness (S*), Simpson’s index 440 
of diversity (1-D), and Shannon-Wiener index of diversity (H’). Error bars represent the standard deviation 441 
of the mean (CD n =21, siblings n =17, and healthy n =19). Asterisks denote significant differences in 442 
comparisons of diversity at the P < 0.05 level determined by two sample t-tests.  443 
 444 
Fig. 3. Analysis of similarities (ANOSIM) of whole, common, and rare microbiota between subject cohorts.  445 
Given is the ANOSIM test statistic (R) and probability (P) that two compared groups are significantly 446 
different at the P < 0.05 level (* denotes P < 0.001 and ** P < 0.0001). ANOSIM R and P values were 447 
generated using the Bray-Curtis measure of similarity. R scales from +1 to -1. +1 indicates that all the most 448 
similar samples are within the same groups. R = 0 occurs if the high and low similarities are perfectly mixed 449 
and bear no relationship to the group. A value of -1 indicates that the most similar samples are all outside 450 
of the groups.  451 
 452 
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Fig. 4. Canonical correspondence biplots for (a) whole, (b) core, and (c) rare microbiota. Red crosses  453 
represent microbiota samples from the CD cohort, yellow filled triangles for the siblings cohort, and green 454 
diamonds for the healthy cohort. In each instance, the 95 % concentration ellipses are given for the CD 455 
(red), siblings (yellow), and healthy (green) cohort microbiota. Biplot lines for clinical variables that 456 
significantly accounted for variation within the microbiota at the P < 0.05 level (see Table 3) show the 457 
direction of increase for each variable, and the length of each line indicates the degree of correlation with 458 
the ordination axes. CCA field labels: Calprotectin, Gender, “T-cells” – Proportion of blood T-cell with 459 
memory phenotype (%), “CD4+ T-cells” – Blood concentration of naïve CD4+ T-cells (cells /ml), “β7 integrin” 460 
– Proportion of CD4 naïve T-cells expressing β7 integrin (%),“GRR” – genotype relative risk, (cumulative 461 
genotype relative risk (GRR) for each participant was calculated across 72 CD-risk loci (detected using the 462 
Illumina Infinium Immunochip), participants were categorised into reduced, average, elevated or high 463 
genotype risk with reference to a population distribution model of CD-risk). Percentage of community 464 
variation explained by each axis is given in parentheses.  465 
  466 
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Supplementary table S1. List of exclusion criteria by group 560 
All participants Patients Siblings  Controls 
Unable to consent due to 
mental illness/ dementia/ 
learning disability 
 
Evidence of active CD as 
defined by a CDAI of greater 
than 150 
Previous diagnosis 
of IBD 
Previous diagnosis 
of IBD 
Current infection with an 
enteric pathogen 
 
Purely perianal CD Symptoms 
fulfilling Rome III 
criteria for IBS 
Symptoms 
fulfilling Rome III 
criteria for IBS 
Use of antibiotics within the 
last month 
 
Change in dose of oral 
steroids within the last 4 
weeks 
 A first or second 
degree relative 
with IBD 
Consumption of any 
probiotic or prebiotic within 
the last month 
 
Dose of steroids exceeding 
10mg prednisolone per day 
or equivalent 
  
Pregnancy or lactation 
 
Change in dose of oral 5-
ASA products within the last 
4 weeks 
  
Participant requiring 
hospitalization 
 
Commencement of 
azathioprine or 
methotrexate within the 
last 4 months, or change in 
dose of these drugs within 
the last 4 weeks 
  
Significant hepatic, renal, 
endocrine, respiratory, 
neurological or 
cardiovascular disease as 
determined by the principal 
investigator 
 
Infusion of biological 
therapies (e.g. infliximab) 
within the last 3 months* 
  
A history of cancer with a 
disease free state of less 
than two years 
 
Use of rectal 5-ASA or 
steroids within the last 2 
weeks 
  
CRP greater than 5mg/L at 
screening, as measured by 
the local laboratory 
 
Use of NSAIDs within the 
last 2 weeks 
  
 Imminent need for surgery   
 Short bowel syndrome   
 Previous proctocolectomy   
* No patient had been previously exposed to biological therapies 561 
  562 
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Supplementary table S2 Bacterial species identified from biopsy samples collected from subject 563 
within the Crohn’s (n = 21), Siblings (n = 17), and Healthy (n = 19) cohorts. Species-level identities 564 
of detected taxa are reported here. However, given the length of the ribosomal sequences 565 
analysed, these identities should be considered putative. C and R denote core or rare species 566 
group membership within each cohort (highlighted in green and yellow, respectively). 567 
 568 
Phylum Class Family Taxon Name Crohn's Siblings Healthy 
Actinobacteria Actinobacteria Actinomycetaceae Actinomyces naeslundii   R 
   Varibaculum cambriense  R R 
  Corynebacteriaceae  Corynebacterium afermentans  R  
   Corynebacterium amycolatum R R R 
   Corynebacterium aurimucosum  R  
   Corynebacterium durum R   
   Corynebacterium glucuronolyticum   R 
   Corynebacterium imitans  R  
   Corynebacterium jeikeium  R R 
   Corynebacterium mucifaciens  R  
   C. pseudogenitalium   R 
  Geodermatophilaceae  Blastococcus saxobsidens  R  
  Intrasporangiaceae Janibacter  R  
  Microbacteriaceae  Agrococcus jejuensis R   
   Arthrobacter agilis  R  
   Microbacterium barkeri  R R 
   Microbacterium paraoxydans  R R 
   Zimmermannella bifida  R  
  Micrococcaceae Micrococcus luteus R R R 
  Mycobacteriaceae  Mycobacterium llatzerense  R  
  Nocardiaceae  Rhodococcus globerulus R R  
  Propionibacteriaceae  Microlunatus aurantiacus   R 
   Propionibacterium acnes R R R 
   P. granulosum  R  
  Pseudonocardiaceae  Saccharopolyspora hirsuta R R R 
  Streptomycetaceae  Streptomyces thermovulgaris R   
  Williamsiaceae  Williamsia muralis   R 
  Bifidobacteriaceae  Bifidobacterium adolescentis R R R 
   Bifidobacterium bifidum R R R 
   Bifidobacterium breve R  R 
   Bifidobacterium longum R R R 
   B.  pseudocatenulatum R R R 
   Bifidobacterium saeculare R   
   Gardnerella vaginalis   R 
  Coriobacteriaceae Adlercreutzia equolifaciens R R R 
   Atopobium vaginae  R R 
   Collinsella aerofaciens R R C 
   Collinsella stercoris  R R 
   Eggerthella hongkongensis R  R 
   Eggerthella lenta R R R 
   Eggerthella sinensis   R 
   Olsenella   R 
   Slackia R  R 
Bacteroidetes  Bacteroidia  Bacteroidaceae  Bacteroides acidifaciens  R R 
   Bacteroides barnesiae   R 
   Bacteroides caccae R R R 
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   Bacteroides capillosus R R R 
   Bacteroides cellulosilyticus R R R 
   Bacteroides coprocola R R  
Table S1 continued       
Phylum Class Family Taxon Name Crohn's Siblings Healthy 
   Bacteroides coprophilus  R R 
   Bacteroides dorei R C R 
   Bacteroides eggerthii R R R 
   Bacteroides faecis R R R 
   Bacteroides finegoldii  R R 
   Bacteroides fragilis R R R 
   Bacteroides intestinalis R R R 
   Bacteroides massiliensis R R R 
   Bacteroides nordii   R 
   Bacteroides ovatus R R R 
   Bacteroides plebeius R R R 
   Bacteroides salyersiae R R R 
   Bacteroides stercoris R R R 
   Bacteroides thetaiotaomicron R R R 
   Bacteroides uniformis R C C 
   Bacteroides vulgatus C C C 
   Bacteroides xylanisolvens R R R 
  Porphyromonadaceae  Dysgonomonas gadei R R C 
   Parabacteroides distasonis R C C 
   Parabacteroides goldsteinii R R R 
   Parabacteroides johnsonii R R R 
   Parabacteroides merdae R R C 
   Porphyromonas levii R R R 
   Porphyromonas somerae R R R 
   Porphyromonas uenonis  R R 
   Tannerella forsythia R R R 
  Prevotellaceae  Prevotella baroniae R R R 
   Prevotella bergensis  R R 
   Prevotella bivia R R R 
   Prevotella buccae  R  
   Prevotella buccalis R R R 
   Prevotella copri R R R 
   Prevotella corporis R R R 
   Prevotella dentasini   R 
   Prevotella disiens R R R 
   Prevotella histicola  R R 
   Prevotella loescheii   R 
   Prevotella melaninogenica  R R 
   Prevotella oulorum  R  
   Prevotella pallens   R 
   Prevotella pleuritidis  R  
   Prevotella ruminicola  R R 
   Prevotella stercorea R R R 
  Rikenellaceae  Alistipes finegoldii R R R 
   Alistipes massiliensis R R R 
   Alistipes putredinis R R R 
 Cytophagia  Cytophagaceae  Hymenobacter  R R 
  Flammeovirgaceae  Rapidithrix thailandica  R  
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 Flavobacteriia  Flavobacteriaceae Chryseobacterium hominis R R  
   Chryseobacterium joostei R R  
 Sphingobacteriia  Chitinophagaceae  Chitinophaga arvensicola R  R 
Deinococcus-Thermus  Deinococci  Deinococcaceae  Deinococcus proteolyticus R   
Firmicutes Bacilli Alicyclobacillaceae  Alicyclobacillus acidoterrestris R   
   Alicyclobacillus vulcanalis   R 
Table S1 continued       
Phylum Class Family Taxon Name Crohn's Siblings Healthy 
  Bacillaceae  Anoxybacillus kestanbolensis  R R 
   Bacillus cereus R C R 
   Bacillus fordii  R  
   Geobacillus stearothermophilus  R  
  Paenibacillaceae  Paenibacillus humicus  R  
  Planococcaceae  Viridibacillus arvi  R  
  Staphylococcaceae  Jeotgalicoccus halotolerans  R R 
   Macrococcus caseolyticus R   
   Salinicoccus roseus  R  
   Staphylococcus aureus R  R 
   Staphylococcus epidermidis R R R 
   Staphylococcus hominis R  R 
  Aerococcaceae Abiotrophia defectiva R R R 
   Aerococcus viridans   R 
   Facklamia ignava  R  
   Facklamia languida  R  
  Carnobacteriaceae Marinilactibacillus psychrotolerans R  R 
  Enterococcaceae Enterococcus avium  R  
   Enterococcus cecorum R R R 
   Enterococcus durans R   
   Enterococcus faecium R  R 
   Enterococcus lactis R  R 
  Lactobacillaceae  Lactobacillus alimentarius  R  
   Lactobacillus crispatus R  R 
   Lactobacillus delbrueckii  R  
   Lactobacillus gasseri R R R 
   Lactobacillus iners R  R 
   Lactobacillus intestinalis R R R 
   Lactobacillus manihotivorans R   
   Lactobacillus mucosae R R R 
   Lactobacillus reuteri  R  
   Lactobacillus vaccinostercus R   
   Lactobacillus zeae R   
   Pediococcus acidilactici R   
  Leuconostocaceae  Weissella cibaria R R  
   Weissella confusa R   
  Streptococcaceae  Lactococcus lactis  R R 
   Streptococcus anginosus R R R 
   Streptococcus bovis R   
   Streptococcus dysgalactiae   R 
   Streptococcus gallinaceus   R 
   Streptococcus gordonii   R 
   Streptococcus mitis R R R 
   Streptococcus oralis R R R 
   Streptococcus parasanguinis R R R 
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   Streptococcus pluranimalium   R 
   Streptococcus thermophilus R R R 
 Clostridia Clostridiaceae Alkaliphilus transvaalensis R R R 
   Clostridium amygdalinum R R R 
   Clostridium asparagiforme R R R 
   Clostridium bartlettii R R R 
   Clostridium bolteae R C C 
   Clostridium butyricum R   
   Clostridium celerecrescens R R R 
Table S1 continued       
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   Clostridium chauvoei  R R 
   Clostridium citroniae R R R 
   Clostridium cocleatum R R R 
   Clostridium difficile R   
   Clostridium disporicum R   
   Clostridium ghonii R  R 
   Clostridium hathewayi R R R 
   Clostridium hylemonae   R 
   Clostridium indolis R R C 
   Clostridium innocuum R R R 
   Clostridium intestinale   R 
   Clostridium lactatifermentans R R R 
   Clostridium lavalense R R R 
   Clostridium leptum R R R 
   C. methoxybenzovorans R R R 
   Clostridium methylpentosum R R C 
   Clostridium orbiscindens R C C 
   Clostridium paraputrificum R   
   Clostridium perfringens R   
   Clostridium puniceum R R R 
   Clostridium ramosum R R R 
   Clostridium saccharolyticum R R R 
   Clostridium scindens R   
   Clostridium spiroforme R R R 
   Clostridium stercorarium R   
   Clostridium straminisolvens R R R 
   Clostridium symbiosum R C R 
   Clostridium termitidis  R R 
   Clostridium thermocellum R R R 
   Clostridium xylanolyticum R R R 
  Clostridiales Family XI Anaerococcus hydrogenalis R R R 
   Anaerococcus lactolyticus   R 
   Anaerococcus octavius R R R 
   Anaerococcus prevotii R R R 
   Finegoldia magna R R R 
   Parvimonas micra R R R 
   Peptoniphilus asaccharolyticus R R R 
   Peptoniphilus ivorii R R R 
   Tissierella praeacuta R R R 
  Clostridiales Family XIII Eubacterium infirmum R R R 
   Eubacterium minutum  R  
   Eubacterium sulci R R R 
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   Mogibacterium pumilum R R R 
  Clostridiales Family XVIII Symbiobacterium thermophilum  R  
  Eubacteriaceae  Eubacterium rectale C C C 
   Eubacterium siraeum R R R 
  Lachnospiraceae Anaerostipes caccae  R  
   Blautia producta R C C 
   Coprococcus catus R R R 
   Coprococcus comes R R R 
   Coprococcus eutactus R R C 
   Dorea formicigenerans R R R 
   Lachnospira pectinoschiza R R R 
   Moryella indoligenes  R R 
Table S1 continued       
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   Pseudobutyrivibrio fibrisolvens R R R 
   Pseudobutyrivibrio ruminis R R R 
   Roseburia faecis R C C 
   Roseburia hominis R R R 
   Roseburia intestinalis R R R 
  Peptococcaceae  Desulfitobacterium hafniense  R R 
  Peptostreptococcaceae Eubacterium yurii  R R 
   Peptostreptococcus anaerobius R R R 
   Peptostreptococcus stomatis  R  
  Ruminococcaceae Anaerotruncus colihominis R R R 
   Faecalibacterium prausnitzii C C C 
   Oscillospira guilliermondii R C C 
   Ruminococcus albus R R R 
   Ruminococcus bromii R C C 
   Ruminococcus callidus R R R 
   Ruminococcus flavefaciens R R R 
   Ruminococcus gnavus C C C 
   Ruminococcus obeum R R C 
   Ruminococcus torques R R C 
  Syntrophomonadaceae  Syntrophomonas curvata   R 
 Erysipelotrichi  Erysipelotrichaceae  Catenibacterium mitsuokai R R R 
   Coprobacillus cateniformis R R R 
   Erysipelothrix rhusiopathiae R   
   Eubacterium biforme R R R 
   Eubacterium cylindroides  R R 
   Holdemania filiformis  R R R 
  Erythrobacteraceae  Solobacterium moorei  R R 
 Negativicutes Acidaminococcaceae Acidaminococcus fermentans R R R 
   Acidaminococcus intestini R R R 
   Phascolarctobacterium R R R 
  Veillonellaceae  Dialister invisus R R C 
   Dialister micraerophilus R R R 
   Dialister pneumosintes R R  
   Dialister succinatiphilus R R R 
   Megamonas hypermegale  R R 
   Megasphaera elsdenii R R R 
   Mitsuokella jalaludinii  R R 
   Mitsuokella multacida R  R 
   Sporomusa aerivorans R   
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   Veillonella dispar R R R 
   Veillonella parvula R R R 
   Victivallis vadensis  R R 
Fusobacteria  Fusobacteria  Fusobacteriaceae Fusobacterium gonidiaformans  R R 
   Fusobacterium nucleatum  R  
   Fusobacterium periodonticum R R R 
   Fusobacterium ulcerans R R R 
  Leptotrichiaceae  Leptotrichia goodfellowii R   
   Sneathia amnionii R R  
   Sneathia sanguinegens   R 
Planctomycetes  Planctomycetia  Planctomycetaceae  Gemmata obscuriglobus R   
Proteobacteria Alphaproteobacteria  Caulobacteraceae Asticcacaulis excentricus  R  
   Brevundimonas nasdae   R 
  Bradyrhizobiaceae  Nitrobacter vulgaris   R 
   Rhodopseudomonas R R R 
Table S1 continued       
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  Methylobacteriaceae  Methylobacterium tardum R R  
  Methylocystaceae  Methylocystis parvus   R 
  Phyllobacteriaceae  Mesorhizobium loti   R 
   Phyllobacterium myrsinacearum R R R 
  Rhodobacteraceae  Labrenzia aggregata  R  
   Loktanella marincola  R  
   Paracoccus alcaliphilus R R  
   Paracoccus koreensis R R  
   Paracoccus marcusii R  R 
   Paracoccus yeei R R R 
   Rubellimicrobium R R  
  Rhodospirillaceae  Rhodocista pekingensis   R 
  Anaplasmataceae Neorickettsia risticii R R R 
  Erythrobacteraceae  Porphyrobacter tepidarius  R  
  Sphingomonadaceae  Sphingobium yanoikuyae   R 
   Sphingomonas asaccharolytica  R R 
   Sphingomonas faeni   R 
 Betaproteobacteria Comamonadaceae Acidovorax facilis R R R 
  Oxalobacteraceae  Massilia timonae R R R 
  Sutterellaceae  Sutterella parvirubra R R R 
   Sutterella wadsworthensis  R C C 
  Burkholderiaceae  Pandoraea pulmonicola   R 
   Ralstonia pickettii R R R 
  Comamonadaceae  Hydrogenophaga taeniospiralis  R  
   Variovorax paradoxus R   
  Hydrogenophilaceae  Hydrogenophilus   R 
  Neisseriaceae  Microvirgula aerodenitrificans  R  
   Neisseria mucosa   R 
   Neisseria subflava   R 
  Burkholderiaceae  Cupriavidus taiwanensis R R  
  Comamonadaceae  Comamonas denitrificans R R  
   Comamonas terrigena  R  
   Comamonas testosteroni R R  
  Rhodocyclaceae Dechloromonas  R  
 Deltaproteobacteria Desulfovibrionaceae  Bilophila wadsworthia  R R 
   Desulfovibrio aespoeensis R   
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   Desulfovibrio piger R R R 
  Myxococcaceae Anaeromyxobacter dehalogenans R   
 Epsilonproteobacteria  Campylobacteraceae  Campylobacter concisus R   
   Campylobacter faecalis   R 
   Campylobacter hominis R R R 
   Campylobacter mucosalis  R  
   Campylobacter ureolyticus R R R 
 Gammaproteobacteria Aeromonadaceae  Aeromonas media R R R 
  Succinivibrionaceae  Succinivibrio   R 
  Shewanellaceae  Shewanella putrefaciens  R R 
  Enterobacteriaceae Shigella boydii R R R 
   Shigella dysenteriae R R R 
   Shigella flexneri C C C 
   Shigella sonnei R R R 
   Citrobacter freundii R R R 
   Cronobacter muytjensii R R R 
   Cronobacter turicensis R   
   Enterobacter hormaechei R R R 
Table S1 continued       
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   Escherichia coli C R R 
   Escherichia fergusonii C C C 
   Klebsiella granulomatis R R R 
   Klebsiella pneumoniae R R R 
   Klebsiella variicola R R R 
   Kluyvera ascorbata R   
   Morganella morganii R   
   Raoultella planticola R  R 
  Oceanospirillaceae Marinospirillum insulare  R  
  Pasteurellaceae Actinobacillus porcitonsillarum   R 
   Haemophilus parainfluenzae R R R 
  Moraxellaceae Acinetobacter johnsonii R R R 
   Acinetobacter junii R R R 
   Acinetobacter lwoffii R  R 
   Acinetobacter radioresistens R   
   Acinetobacter schindleri  R  
   Enhydrobacter aerosaccus  R R 
  Pseudomonadaceae Pseudomonas aeruginosa R R R 
   Pseudomonas geniculata R R C 
   Pseudomonas mendocina  R  
   Pseudomonas putida R R R 
   Pseudomonas veronii  R R 
  Xanthomonadaceae  Stenotrophomonas  R R 
   Thermomonas dokdonensis   R 
   Xanthomonas vesicatoria R R R 
Spirochaetes Spirochaetes Brachyspiraceae  Brachyspira aalborgi   R 
Synergistetes  Synergistia Synergistaceae  Jonquetella anthropi  R  
   Pyramidobacter piscolens  R R 
   Synergistes jonesii   R 
Tenericutes Mollicutes Acholeplasmataceae Acholeplasma  R  
   Acholeplasma parvum  R R 
Verrucomicrobia Verrucomicrobiae  Verrucomicrobiaceae  Akkermansia muciniphila R R R 
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Supplementary methods 569 
Peripheral blood T-cell flow cytometry 570 
The fluorescently labeled antibodies used were: anti-CD3 Pacific Blue (clone OKT3, Biolegend, San Diego, 571 
CA,USA), anti-CD45RA PE-Cy7 (clone L48, BD Bioscience, Franklin Lakes, NJ, USA), anti-CD8 PerCP-Cy5.5 572 
(clone SK1, BD Bioscience) and anti-CD4 APC (clone RPA-T4, BD Bioscience), anti-β7 PE (clone FIB504, BD 573 
Pharmingen). 574 
Isotype-matched controls for mIgG1κ PE-Cy7 (clone MOPC-21, BD Pharmingen), rat IgG2a PE (clone R35-95, 575 
BD Bioscience), mIgG1 PE (clone MOPC-21, BD Bioscience), rIgM FITC (clone R4-22, BD Pharmingen) and 576 
mIgG1 FITC (clone MOPC-21, BD Pharmingen) were used to set positive and negative regions for gating 577 
during analysis. Anti-CD8 FITC (clone LT8, AbD Serotec, Kidlington, UK), anti-β7 PE (clone FIB504, BD 578 
Pharmingen), anti-CD8 PerCP-Cy5.5 (clone SK1, BD Bioscience), anti-CD45RA PE-Cy7 (clone L48, BD 579 
Bioscience) anti-CD3 PB (clone OKT3, Biologend) and anti-CD4 APC (clone RPA-T4, BD Bioscience) 580 
conjugated antibodies were used for off-line compensation. 581 
 582 
Gut mucosal microbiota 583 
DNA extraction protocol 584 
Biopsy DNA extraction was carried out using a phenol/chloroform based method, as follows: Guanidinium 585 
thiocyanate–EDTA–sarkosyl (500 μL) and PBS (500 μL), pH 8.0, were added to biopsy samples. Cell 586 
disruption was achieved using a Fastprep-24 Instrument (MP Biomedicals Europe, Illkirch, France) 6.5 m/s, 587 
60 s, followed by incubation at 90 °C for 1 min and −20 °C for 5 min. Cell debris was pelleted by 588 
centrifugation at 12 000 × g for 2 min at 4 °C. Supernatant was transferred to a fresh microfuge tube. NaCl 589 
(to a final concentration of 0.5 mol/L and polyethylene glycol (to a final concentration of 15%) were added 590 
and DNA precipitated at 4 °C for 30 min. DNA was pelleted by centrifugation at 12 000 × g for 2min at 4 °C 591 
and resuspended in 300 μL of sterile distilled water. Samples were heated at 90 °C for 30 s and vortexed. 592 
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Phenol/chloroform (1:1) (300 μL) was added, and samples were vortexed for 20 s before centrifugation at 593 
12 000 × g at 4 °C for 3min. The upper phase was then transferred to a fresh microfuge tube. Total DNA was 594 
then precipitated by the addition of an equal volume of isopropanol, a 0.1-volume 10 mol/L ammonium 595 
acetate, and 1 μL of GenElute linear polyacrylamide (Sigma-Aldrich, Gillingham, UK) and incubated at −20 °C 596 
for 25 min. DNA was pelleted by centrifugation at 12 000 × g at 4 °C for 5 min. Pelleted DNA was then 597 
washed 3 times in 70% ethanol, dried, and resuspended in 50 μL of sterile distilled water. DNA extracts 598 
were quantified using the Picodrop Microlitre Spectrophotometer (GRI, Braintree, UK). Negative controls, 599 
consisting of sterile water, were included in the PMA treatment, DNA extraction, and PCR amplification 600 
steps. 601 
16S rRNA gene sequencing 602 
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed as described previously using 603 
Gray28F 5'-TTTGATCNTGGCTCAG-3' and Gray519r 5'-GTNTTACNGCGGCKGCTG-3').1 A single-step 30 cycle 604 
PCR using HotStarTaq Plus Master Mix Kit (Qiagen, Valencia, CA) performed under the following conditions: 605 
94°C for 5minutes, followed by 28 cycles of: 94°C for 30 seconds, 53°C for 40 seconds, and 72°C for 1 606 
minute. Amplification was followed by a final elongation step at 72°C for 5 minutes. Following PCR, all 607 
amplicon products from different samples were mixed in equal concentrations and purified using 608 
Agencourt Ampure beads (Agencourt Bioscience Corporation, MA, USA). Samples were sequenced utilizing 609 
Roche 454 FLX titanium instruments and reagents following manufacturer’s guidelines.  610 
Sequence data analysis was carried out. Here, the Q25 sequence data derived from the sequencing process 611 
was processed using standard analysis pipeline processes (MR DNA, Shallowater, USA). Sequences were 612 
depleted of barcodes and primers then short sequences, 200 bp removed, as were sequences with 613 
ambiguous base calls removed, and sequences with homopolymer runs exceeding 6 bp, sequences were 614 
denoised and chimeras removed.2-8 Operational taxonomic units were defined after removal of singleton 615 
sequences, clustering at 3% divergence (97% similarity). Final OTUs were taxonomically classified using 616 
BLASTn against a curated databased derived fromGreenGenes, NCBI and RDP databases.9 Normalized and 617 
47 
 
 
de-noised files were then rarefied and run through QIIME10 to generate alpha and beta diversity data. 618 
Additional statistical analyses were performed with NCSS2007 (NCSS, UT) and XLstat 2012 (Addinsoft, NY). 619 
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